Knowledge

The term CGT stands for Cell and Gene Therapy and describes a range of new personalized therapies that are promising in the treatment of some diseases. For which diseases is the therapy suitable?

The big names in the pharmaceutical industry are increasingly switching from immobile systems based on bulky stainless steel tankers to scalable single-use filtration systems. But why is this so?

Single-use technologies, which reduce the risk of cross-contamination of high-quality bulk drug substances, are becoming increasingly popular in the pharmaceutical industry. You can find out the reason for this in the blog post!
 

Given the increasing importance of drug substances in the pharmaceutical industry, the need for reliable freeze-thaw processes is becoming more and more important. For further information and details please see our Case Study!

The Single Use Bag has many advantages in the manufacturing and development process of biopharmaceutical products. Find out what these advantages are in this blog post!

Due to the use of disposable systems, which are disposed of after use, single use technologies appear at first glance to be a major environmental burden. How it looks like in reality, you can find out here!

It is not always easy to decide whether to utilize single use systems or stainless steel devices for the production of biopharmaceuticals. Find out about the differences between single use technology and stainless steel reactors in terms of safety, costs, use of energy, efficiency and more – in this article.

The fill and drain process for biopharmaceutical products can be a massive challenge for the biopharma industry. Here, single use systems offer a multitude of advantages.

Test our RoSS.pFTU lab scale – the perfect freeze and thaw technology for single use bags that is completely standalone, meaning it is compatible with any established bag brand. You can rent our freeze-thaw platform for up to three months. You will be reimbursed for the rent paid if you choose to purchase the platform.

According to information from the biopharmaceutical industry, the loss rate for CAR-T cell therapies is over 1%. This means that it can be assumed that currently only 99 out of 100 people receive a fully functional Car-T therapy. Read here!

The National Health Service (NHS) of Great Britain, confirms the use of CAR-T Cell Therapy Kymriah on an 11-year-old leukaemia patient. However, it is not certain whether the vital therapy will make its way into society. Read it for yourself!
 

Due to increased efficiency, flexibility and cost reduction, it has become standard practice to use integrated single use freeze-thaw systems with single use bags, tubing and connectors. Find out what the reasons for this are here!